Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor
epacadostat will be tested together for the first time in patients with recurrent ovarian,
fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating
activity of the combination of these agents.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImmunoVaccine Technologies, Inc. ImmunoVaccine Technologies, Inc. (IMV Inc.)